Creso Pharma Limited Stock EBITDA

COPHFDelisted Stock  USD 0.12  0.00  0.00%   
Creso Pharma Limited fundamentals help investors to digest information that contributes to Creso Pharma's financial success or failures. It also enables traders to predict the movement of Creso Pink Sheet. The fundamental analysis module provides a way to measure Creso Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Creso Pharma pink sheet.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Creso Pharma Limited Company EBITDA Analysis

Creso Pharma's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

EBITDA

 = 

Revenue

-

Basic Expenses

More About EBITDA | All Equity Analysis

Current Creso Pharma EBITDA

    
  (28.06 M)  
Most of Creso Pharma's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Creso Pharma Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Competition

According to the company disclosure, Creso Pharma Limited reported earnings before interest,tax, depreciation and amortization of (28.06 Million). This is 103.2% lower than that of the Healthcare sector and significantly lower than that of the Drug Manufacturers—Specialty & Generic industry. The ebitda for all United States stocks is 100.72% higher than that of the company.

Creso EBITDA Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Creso Pharma's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Creso Pharma could also be used in its relative valuation, which is a method of valuing Creso Pharma by comparing valuation metrics of similar companies.
Creso Pharma is currently under evaluation in ebitda category among its peers.

Creso Fundamentals

About Creso Pharma Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Creso Pharma Limited's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Creso Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Creso Pharma Limited based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.
You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.

Other Consideration for investing in Creso Pink Sheet

If you are still planning to invest in Creso Pharma Limited check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Creso Pharma's history and understand the potential risks before investing.
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Bonds Directory
Find actively traded corporate debentures issued by US companies
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges